Introduction
Specific phobia is one of the most common mental disorders in the general population with lifetime and 12-month prevalence estimates in representative population surveys ranging from 7.7% to 12.5% and from 2.0% to 8.8%, respectively (Kessler et al., 1994; 2005; Bijl et al., 1998; de Graaf et al., 2012; Stinson et al., 2007; Alonso et al., 2004; Grenier et al., 2011; Wells et al., 2006) . In addition, prospective studies have shown high incidence rates for specific phobia. Angst et al. (2016) found a cumulative incidence of 26.9% between ages 20 and 50 years. Bijl et al. (2002) found a 1-year incidence rate of 2.20 new cases per 100 person-years. Grant et al. (2009) found a lower 1-year incidence rate of 0.44 new cases per 100 person-years. Interestingly, prevalence rates (e.g. Kessler et al., 1994; Bijl et al., 1998; Stinson et al., 2007) and incidence rates (Bijl et al., 2002; Angst et al., 2016) have been found to be higher in females than in males. Also, prevalence rates have been shown to decrease with age (e.g. Stinson et al., 2007; Sigström et al., 2016) .
Because of its high prevalence, lifetime persistence (e.g. Goisman et al., 1998) , associated impairment and high lifetime comorbidity rate with other disorders, specific phobia is important from both an epidemiological and a clinical perspective. Previous work has shown considerable role impairment in those with specific phobia, with 34.2% reporting significant role impairments in their daily life, compared to 26.5% in agoraphobia and 33.5% in social phobia (Magee et al., 1996) . Depla et al. (2008) showed that up to 59.2% of patients reported interference with their daily life. Using data from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), Stinson et al. (2007) showed that impairment levels in specific phobia were comparable with other anxiety-and substance-use disorders.
However, other studies have found low disability in specific phobia compared to other disorders (e.g. Wells et al., 2006; Ormel et al., 2008) and it has been suggested that observed functional impairment in specific phobia can be partly explained by high co-occurrence with other disorders (Comer et al., 2011) . Nevertheless, the restricted lifestyle resulting from fear and avoidance in specific phobia is likely to contribute independently to functional impairment.
Previous surveys have shown that comorbidity rates between specific phobia and other mental disorders are high (Kessler et al., 1996; 1997) , with estimated rates of up to 81.0% (Magee et al., 1996) . Interestingly, these retrospective studies showed that in the majority of comorbid cases, the onset of specific phobia precedes the other disorder(s) (Magee et al., 1996; Kessler et al., 1996; 1997) . Prospective work has shown that specific phobia is associated with a higher odds of later depressive, anxiety and eating disorders (Goodwin et al., 2002; Bittner et al., 2004; Trumpf et al., 2010; Lieb et al., 2016) but not of later substanceuse disorders (Zimmermann et al., 2003) . Grant et al. (2009) showed that specific phobia at baseline was associated with an increased incidence of other anxiety disorders. However, these associations could also be explained by other baseline disorders and sociodemographic factors.
Relatively effective treatments, such as behavior therapy and cognitive therapy are available for specific phobia (Choy et al., 2007) . However, despite specific-phobia patients' need for care, only a minority of patients seeks treatment in their lifetime (Stinson et al., 2007: 8.0%; Magee et al., 1996: 46.6%) . In addition it has been shown that specific phobia patients that do seek treatment take much longer to do so compared to other anxiety disorders (Ten Have et al., 2013; Iza et al., 2013) .
Within specific phobia, the DSM distinguishes between different subtypes: animal (e.g. bugs, snakes), natural environment (e.g. heights, weather), blood-injection-injury, situational (e.g. flying on a plane, enclosed spaces) and other (e.g. vomiting, choking).
Previously phobia subtypes have been shown to differ in terms of e.g. prevalence, impairment levels and comorbidity rates (e.g. Frederikson et al., 1996; Becker et al., 2007; Depla et al., 2008; Lebeau et al., 2011) . Also, most patients have more than one subtype (Curtis et al., 1998; Burstein et al., 2012) and increasing numbers of subtypes have been shown to be associated with more comorbidity, impairment and treatment-seeking (e.g. Curtis et al., 1998; Stinson et al., 2007; Burstein et al., 2012 ).
Although the above described findings indicate that specific phobia a highly relevant condition that deserves attention from both researchers and clinicians, they all come from surveys in western, high income countries. This makes it hard to judge the universal relevance of specific phobia as an impairing condition and a marker for increased psychopathology risk.
In this study we therefore took a cross-national approach, combining World Mental Health (WMH) population survey data from 22 low/lower-middle income, upper-middle income and high-income countries (n=124,902) to gain a more complete insight into the epidemiological characteristics of specific phobia around the world. Ireland, Poland, Portugal, Spain and the USA). The sample sizes of the surveys ranged from 2,357 (Romania) to 12,790 (New Zealand) and the total combined sample size was 124,902.
Method

Sample
Most surveys were based on nationally representative stratified multistage clustered area probability samples of household residents. All respondents were 18 years or older. Response rates ranged from 45.9% (France) to 97.2% (Colombia) and the average weighted response rate across countries was 69.3%. The surveys were conducted face-to-face by trained lay interviewers. The same standardized procedures for interviewer training, translation of the used study materials and quality control were used in all countries (Kessler & Üstün, 2008) ].
To reduce the burden of the interview it was often divided into two parts. In Part I, core mental disorders were assessed. In Part II, additional disorders and correlates were assessed.
All respondents completed part I (n=124,902). Part II (n=60,345) was additionally administered to a subsample of respondents meeting criteria for any Part I disorder and in a probability subsample of the other part I respondents. Part II responses were weighted by the inverse of their probability of selection into the part II sample to adjust for any differential sampling. All respondents provided informed consent prior to the interview and the study protocols were approved by the institutional review boards of the organizations coordinating the surveys.
Measures
Diagnostic assessments
The lifetime and 12-month prevalence and AOO of specific phobia as defined in the Diagnostic and Statistical Manual, fourth edition was evaluated with the World Health Organization Composite International Diagnostic Interview (CIDI). In the screening section, respondents were shown a list of six specific fears (animals, still water/weather events, blood/injuries/medical experiences [BIM] , closed spaces, high places, flying) and were asked if they ever had a strong fear of any of these things. If any specific fear was reported in the screening section, the specific phobia section was administered. The CIDI was also used to assess other psychiatric disorders, including mood (major depressive, dysthymic, bipolar-I, bipolar-II and sub-threshold bipolar disorder) anxiety (agoraphobia, social phobia, generalized anxiety, panic, post-traumatic stress and separation anxiety) substance use (alcohol and drug abuse, alcohol and drug dependence with abuse) and behavior disorders (attention-deficit/hyperactivity, oppositional-defiant, conduct, intermittent explosive disorder). The WMH interview translation, back-translation and harmonization was done by culturally competent bilingual clinicians, who reviewed, modified, and approved the key phrases describing the assessed symptoms (Harkness et al., 2008) . Masked clinical reappraisal with a standardized clinical interview showed fair agreement for specific phobia (area under the receiver operating curve=0.67; Haro et al., 2006) .
Healthcare use
The services module of the WMH-CIDI v3.0 (Kessler & Üstün, 2004 ) was used to assess if respondents ever received treatment for emotion regulation problems, psychological distress, anxiety, or substance use. If respondents reported ever receiving such care, follow-up questions were asked about their age at the first and last treatment and about the treatment they received in the past 12 months. Different sectors of treatment were distinguished. The specialty mental health sector included psychiatrists, psychologists or any other nonpsychiatrist mental health specialists (social workers, counselors in specialty mental health settings, mental health helplines, overnight hospital admissions for mental health or substance-related problems). The general medical sector included general practitioners, other medical doctors, nurses, occupational therapists or any other healthcare professional. The human services sector included religious or spiritual advisors, social workers or counsellors in other settings than the specialty mental health sector. The complementary and alternative medicine (CAM) sector included any other type of healer (e.g. herbal healers, self-help groups).
Impairment
A modified version of the Sheehan Disability Scales (SDS; Leon et al., 1997) was used to assess 12-month role-functioning. Respondents were asked to remember the month in which their specific phobia was most severe and to rate its interference with functioning in four domains (home management, ability to work, relationships and social life) on a 10-point scale. Those with a score of 7 or higher on one or more SDS-domains were classified as severely impaired. Respondents with 12-month specific phobia were also asked how many of the 365 days in the past 12 months they had been totally unable to work or carry out their normal activities because of their specific phobia.
Demographic factors
The following demographic factors were investigated: age-group (18-29 years, 30-44 years, 45-59 years and 60+ years), gender, employment status (employed, student, homemaker, retired, other [unemployed, temporarily laid off, maternity leave, illness/sick leave, and disabled]), marital status (currently married, divorced/separated/widowed, never married), education level (no education, some primary, finished primary, some secondary, finished secondary, some college, finished college) and household income (low, low-average, highaverage and high). Income categories were based on the quartiles of country-specific gross household income distributions (Levinson et al., 2010) .
Statistical analyses
Analyses of prevalence, AOO and impairment were carried out for the cross-national sample, each country-income group, each country survey, and cross-national gender-groups. Crosstabulations were used to estimate the lifetime, 12-month and 30-day prevalence. Only lifetime prevalence rates were calculated for subtypes of specific phobia and the prevalence of specific phobia with 1 to ≥4 lifetime subtypes.
The 12-month prevalence of specific phobia among lifetime cases was used as an indicator of recurrence or chronicity: e.g. a disorder can have a high lifetime prevalence, but a low level of recurrence as shown by a low 12-month prevalence among lifetime cases. The 30-day prevalence among 12-month cases was calculated as an indicator of disorder duration:
e.g. a disorder can have a high 12-month prevalence, but a limited duration, as shown by a low 30-day prevalence. The percentages of lifetime and 12-month comorbidity in lifetime cases and the percentages of 12-month comorbidity in 12-month cases were estimated. In addition, the percentages of cases in which specific phobia was the temporally primary disorder were calculated. The percentages of 12-month specific phobia cases with severe role impairment and healthcare use across sectors were calculated with cross-tabulation. The mean number of days out of role was calculated for all 12-month specific phobia cases combined and for subsamples of 12-month cases, split out by their highest reported domain of roleimpairment. Percentages of lifetime comorbidity, 12-month impairment and healthcare-use were calculated for each subtype and groups with 1 to ≥4 lifetime subtypes.
The AOO and the projected risk at age 75 were estimated with the two-part actuarial method implemented in SAS. The actuarial method assumes a constant conditional risk of onset in a given year of life across cohorts and allows for accurate estimations of the onset timings within a year (Halli et al., 1992) . Associations of lifetime specific phobia with demographic factors were analyzed with survival models, adjusted for age cohort, gender, person-years and country. Associations of 30-day specific phobia with demographic factors were analyzed with logistic regression models, adjusted for time since specific phobia onset, AOO, gender and country. Associations of demographic factors with recurrence (12-month prevalence among lifetime cases) and duration (30-day prevalence among 12-month cases) were analyzed with logistic regression, adjusted for time since specific phobia onset, AOO, gender and country. The distributions of AOO and of sociodemographic were calculated for groups with different subtypes and subgroups with 1 to ≥4 lifetime subtypes.
All analyses were weighted to adjust for differential selection probabilities within households, to match the samples to population sociodemographic distributions and to adjust for nonresponse (Kessler & Üstün, 2008) . Design-adjusted standard errors were estimated using the Taylor series linearization method (Wolter, 1985) , implemented in SAS 9.4 (SAS Institute Inc., Cary, North Carolina). Design-adjusted Wald χ 2 -tests were used to test the multivariate statistical significance of sets of predictors.
Results
Prevalence
Lifetime specific phobia prevalence ranged from 2.6% to 12.5% across countries (Table 1) and the averaged cross-national lifetime prevalence in was 7.4% for the whole sample (median=6.8%; IQR=4.8%-10.2%), 4.9% for the male and 9.8% for the female subsample.
The prevalence was 8.0-8.1% in high income and upper-middle income countries and 5.7% in the low-lower middle income countries. The overall mean 12-month prevalence was 5.5% in the whole sample (median=5.0%; IQR=3.8%-7.6%), 3.3% among males and 7.7% among females. The 12-month prevalence differed across countries (1.7%-10.6%) and income groups (4.0%-6.4%), with the lowest prevalence in the low-lower middle income group (4.0%). The overall mean 30-day prevalence was 3.9% in the total sample, with differences across gender (males: 2.1%; females: 5.5%), countries (1.0%-8.8%) and income groups (2.4%-4.8%), with the lowest prevalence (2.4%) in the low-lower middle income countries.
Of specific phobia subtypes (Table 2) , animal fear had the highest cross-national lifetime prevalence (3.8%), followed by BIM (3.0%), high places (2.8%) and still water or weather events fear (2.3%). Fear of flying had the lowest prevalence (1.3%). The low-lower middle income countries showed the lowest prevalence rates for all subtypes (0.6%-1.6%) and considerably higher prevalence rates in upper-middle income countries (1.2%-4.4%) and high income countries (1.7%-3.7%). The clearest difference was seen for fear of flying, which had an almost three times higher prevalence in high income (1.7%) than in low-lower middle income (0.6%) countries. All subtypes were most common in females. Of the cross-national sample, 3.4% reported a single subtype, 1.8% reported two subtypes, 1.1% reported three subtypes and 1.1% reported ≥4 subtypes. Higher numbers of subtypes were more common among females than males.
Recurrence and duration
The averaged prevalence of 12-month specific phobia among lifetime specific phobia cases was 74.2% for the whole cross-national sample (median=73.0%, IQR=70.2%-81.3%; Table   1 ). The averaged prevalence of 30-day specific phobia among 12-month cases was 70.2% for the cross-national sample (median=72.6%, IQR=67.6%-78.3%). Both prevalence-rates were higher in females than in males. In addition, the 30-day prevalence among 12-month cases was the only that differed notably across income groups, with the lowest rate in the low-low middle income group (58.7%).
AOO
The median AOO was 8 years (IQR=5-13; Appendix Table 2 ) and differed slightly across surveys (IQR=8-9 years). The cross-national projected risk at age 75 was only 0.7% higher than the observed lifetime prevalence rate (8.1% vs. 7.4%), reflecting specific phobia's young AOO distribution. Early AOO was most common for all subtypes, but especially common for fear of still water/weather (Table 3; 37.1%), animals (36.6%), and closed spaces (35.2%). A slightly older onset distribution was seen for fear of flying and high places. Early onset rates increased and late onset rates decreased with the number of fears.
Comorbidity
In 60.5% of lifetime specific phobia cases, at least one other lifetime disorder was present, with 34.3% having a comorbid mood disorder, 41.2% an anxiety disorder, 15.9% a substanceuse disorder, and 17.4% an impulse-control disorder ( Table 4 ). In those with 12-month comorbidity of specific phobia with any other disorder, comorbid anxiety disorders were most common (29.6%), followed by mood disorders (21.0%). Specific phobia preceded the other disorders in the majority of comorbid cases (71.6%-92.2%). Lifetime comorbidity with any other disorder ranged from 60.6% to 73.0% across subtypes ( Table 3) . Comorbidity was highest with anxiety (range: 41.1%-58.8%) and mood disorders (range: 34.7%-43.6%).
Comorbidity rates were highest in those with fear of closed spaces and flying and increased with the number of subtypes from 49.7% (one subtype) to 82.1% (≥4 subtype).
Demographic correlates of specific phobia onset
In the combined sample, higher risk of lifetime onset of specific phobia ( Table 5) and having a lower education than finished college (OR=1.2-1.9).
The age-group distribution varied across subtypes (Table 3) , with most young persons in animal and BIM phobia. The percentage of females was highest in all subtype groups and increased with number of subtypes. Employment status showed limited variation across subtypes, but the percentage of working persons was markedly lower (53.1%) in those with ≥4 subtypes compared to those with 1-3 subtypes (57.7%-60.8%). The percentages of cases with completed college showed some variation across subtypes (8.8%-12.8%), but a more striking difference between those with ≥4 subtypes (7.6%) and those with 1-3 subtypes (12.1%-13.8%). Income-group distributions showed limited variation across subtypes, but the percentages of low-and low-mid income increased with the number of subtypes.
Demographic correlates of persistence
12-month specific phobia prevalence among lifetime cases ( Table 5 ) was higher in those with early AOO compared to those with late AOO (OR=1.4), in women compared to men (OR=1.8), in those who were retired or had employment status 'other' compared to the employed (OR=1.3 and OR=1.5), in those with some college or less compared to those with finished college (OR=1.3-1.7), and in those with low income compared to those with high income (OR=1.4). Only female gender was consistently observed to be associated with an increased odds of 30-day prevalence among 12-month cases (OR=1.5-1.9; Appendix Tables   3-5) .
Impairment
In the combined sample, 18.7% of 12-month specific phobia cases reported severe role impairment in any domain (Appendix Table 6 ), with the highest percentage of severe impairment in the home domain (10.3%) and the lowest in the relationship domain (7.9%).
The percentages of severe impairment differed across income groups on all domains, except for work. The low-lower middle income group, especially Nigeria and PRC Shen Zhen,
showed the lowest percentages of severe impairment. The upper-middle income group showed the highest percentages of severe impairment (range: 9.9-14.4%). The mean number of days out of role in the past year due to 12-month specific phobia was 12.2 (SE=0.9).
However, those with severe impairment in any domain reported 29.1 days out of role (Appendix Table 7 ), with the number of days varying depending on the investigated domain of impairment (34.6-47.9). The percentage of cases reporting any impairment varied somewhat across subtypes (52.1%-57.3%; Table 3 ). However, impairment rates increased with the number of fear subtypes, with 11.6% reporting severe impairment in those with one subtype and 20.6% in those with ≥4 subtypes.
Treatment
Cross-nationally, the percentage of 12-month specific phobia cases reporting any treatment was 23.1%. Treatment was more common in those reporting severe impairment (32.5%) compared to those reporting mild or moderate impairment (respectively, 21.1% and 22.8%;
Appendix Table 8 ). Treatment rates differed across income groups, with 9.6% in low-lower middle income, 16.0% in higher middle income, and 30.1% in high income countries. Overall treatment use showed some variation across subtypes (Table 3) , with the highest rates for fear of flying (28.4%), closed spaces (27.5%), and high places (26.0%). Also, rates of treatment use increased from 16.7% in those with one subtype to 29.7% in those with ≥4 subtypes.
Discussion
Specific phobia is a common mental disorder with a cross-national lifetime prevalence of 7.4%. Interestingly, the prevalence, impairment and duration of specific phobia were considerably higher in high-and upper-middle income countries than in low-lower middle income countries. This could be due to cultural differences in the degree to which symptoms of specific phobia are recognized or attributed to a mental disorder and differences in catastrophic cognitions about phobic/anxious symptoms (Hinton & Pollack, 2009; Marques et al., 2011; Hofmann & Hinton, 2014) . Also, there could be differences in how interview questions are interpreted, social norms, attitudes, and stigmas surrounding mental problems (Angermeyer & Dietrich, 2006; Lee et al., 2009 ). For instance, differences in specific phobia duration could be attributed to the reasons above but could also reflect differences in the kinds and/or frequencies of reported phobic stimuli. Although cross-national differences could not be investigated in-depth, the results suggest that the phenomenology and underlying processes of specific phobia vary across countries. As observed previously (e.g. Stinson et al., 2007; Lebeau et al., 2010) , females showed higher specific-phobia prevalence than males.
Young age was also observed to be associated with specific phobia, aligning with previous work (Stinson et al., 2007; Sigström et al., 2016) . Those with lower education had higher odds of specific phobia, which has been observed previously (Magee et al., 1996) but not in all surveys (Stinson et al., 2007) . Those with employment-status 'Other' (e.g. disabled, looking for job) showed higher odds of specific phobia. Magee et al (1996) found a similar association, but it has not been investigated in other surveys.
Subtype-specific analyses showed that animal phobia had the highest cross-national prevalence (3.0%; 1.4-8.7% across countries), in line with previous observations (3.3%-7.0%; Lebeau et al., 2010; Curtis et al., 1998; Depla et al., 2008) . Fear of still water or weather events had a prevalence of 2.3%, aligning with previously reported prevalence rates for 'water' phobia (2.2-3.4%) and 'storm' phobia (2.0-2.9%; Lebeau et al., 2011) . For fear of heights, the cross-national prevalence (2.8%) was somewhat lower than reported previously (3.1-5.3%; Lebeau et al., 2011) . The cross-national prevalence of BIM phobia (3.0%) was in line with previously estimated prevalence rates (3.2-4.5%; Lebeau et al., 2011) . The crossnational prevalence rates fear of closed spaces (2.2%) and fear of flying (1.3%) were both lower than reported previously (closed spaces: 3.2%-3.3%; flying: 2.5%-2.9%; Lebeau et al., 2010) . Apart from methodological differences, some of the discrepancies between current and previous findings could be explained by variations across countries in culture (see above) and rates of exposure (e.g. flying is less common in low-income countries). Investigation of subtype co-occurrence showed that more than half of patients had two or more lifetime fear subtypes and that those with more subtypes had more severe clinical characteristics (e.g. impairment, comorbidity), aligning with previous results (e.g. Curtis et al., 1998).
The median AOO of specific phobia was found to be young, showing relatively limited variation across surveys (IQR=5-13 years). In line with this, the projected lifetime risk was only slightly higher than the observed lifetime prevalence rates (range of absolute differences across surveys: 0.1%-1.2%; range of proportional differences across surveys:
1.7%-22.0%). In line with previous work (e.g. Burstein et al., 2012) , the AOO distribution showed some differences across subtypes, with more early AOO for animal and natural phenomena phobias. The observation of a younger AOO distribution in those with multiple fear subtypes also aligns with previous work (Burstein et al., 2012) . Lifetime comorbidity levels in specific phobia were high (60.5%), with some subtypes being associated with higher levels than others. In the majority of comorbid cases, specific phobia onset preceded the other disorders(s). In addition, comorbidity became more common with increasing numbers of fear subtypes. Together, these results support the idea that specific phobia is an early-life indicator of psychopathology vulnerability.
Severe role impairment was reported in roughly a fifth of 12-month specific phobia cases, but reported impairment was lower in low-lower middle income countries than in the other countries. The mean number of days out of role in all subjects with 12-month specific phobia was 12.2, but in respondents reporting severe impairment, this number was much higher, often in excess of a month, depending on the domain of severe impairment. 12-month impairment increased with the number of reported fear subtypes, aligning with the idea that the presence of multiple lifetime fears marks increased clinical severity. Together, these results suggests that specific phobia can have severe impact on persons' lives.
Treatment for specific phobia was threefold higher in high-income countries than in low-lower middle income countries, which could be due to differences in the availability of The current study had several limitations. First, diagnoses were based on structured lay interviews. However, a previous clinical reappraisal study (Haro et al., 2006) showed sufficient concordance between CIDI-based and clinical diagnoses of specific phobia. Second, all information about lifetime prevalence and AOO was reported retrospectively. This could have led to recall bias, which has been suggested to lead to underestimated lifetime prevalence rates of common mental disorders (Moffitt et al., 2010) . If this bias affected reporting of specific phobia in the current study, the true lifetime prevalence and comorbidity rates could be higher. Third, the included surveys differed in terms of their response rate and sampling frames. Fifth, not all phobia types were systematically assessed (e.g. fear of choking, vomiting, contacting an illness), which could have led to underreporting. Finally, the results are based on DSM-IV criteria for specific phobia and using DSM-5 diagnoses could have led to different results. Going from DSM-IV to DSM-5, two important modifications were made to the diagnostic criteria. First, persons above 18 are no longer required to recognize that their fear/avoidance is excessive/unreasonable. Second, the fear/avoidance should at least last 6 months in all persons. Interestingly, the former modification is likely to increase prevalence, whereas the latter is likely to decrease the prevalence, possibly counteracting each other's effects. Given the fact that the core features have remained the same and the nature of the modifications, strongly differing prevalence estimations would not be expected.
Although cross-national differences were observed in the prevalence, associated impairment and treatment use, the results suggest that specific phobia is associated with considerable impairment across the world and often precedes other disorders. These findings suggest that specific phobia deserves attention of clinicians and researchers in view of its direct effects on the global burden of disease, and its role in the developmental unfolding of psychopathology. Percentage of respondents with 12 month specific phobia who also meet 12 month criteria for at least one of the other disorders. h Percentage of respondents with either lifetime or 12 month specific phobia and at least 1 of the other disorders, whose age of onset of specific phobia is reported to be younger than the age of onset of all comorbid disorders under consideration (ie, either mood, anxiety, substance use, impulse control or any disorder). 
Education level
No education 1.7* (1.3-2.2) 1.4* (1.1-1.6) 1.7* (1.1-2.6) 1.7* (1.1-2.6) Some primary 2.2* (1.9-2.5) 1.7* (1.6-1.9) 1.7* (1.2-2.2) 1.4* (1.0-1.8) Finished primary 1.9* (1.6-2.3) 1.5* (1.4-1.7) 1.5* (1.1-2.0) 1.4 (1.0-1.8) Some secondary 1.7* (1.5-1.9) 1.5* (1.4-1.6) 1.3* (1.1-1.7) 1.2 (0.9-1.5) Finished secondary 1.5* (1.3-1.7) 1.3* (1.2-1.4) 1.3* (1.1-1.6) 1.3* (1.0-1.6) Some college 5130258 9583 7140 *Significant at the .05 level, 2 sided test. a These estimates are based on logistic regression adjusted for age, gender and country. b These estimates are based on survival models adjusted for age-cohorts, gender, person-years and country. c These estimates are based on logistic regression adjusted for time since specific phobia onset, age of onset, gender and country. d Chi square test of significant differences between blocks of sociodemographic variables. e Denominator N: 124,902 = total sample; 5,130,258 = number of person-years in the survival models; 9,583 = number of lifetime cases of specific phobia; 7,140 = number of 12-month cases of specific phobia. f includes e.g. looking for work or being disabled. c Most WMH surveys are based on stratified multistage clustered area probability household samples in which samples of areas equivalent to counties or municipalities in the US were selected in the first stage followed by one or more subsequent stages of geographic sampling (e.g., towns within counties, blocks within towns, households within blocks) to arrive at a sample of households, in each of which a listing of household members was created and one or two people were selected from this listing to be interviewed. No substitution was allowed when the originally sampled household resident could not be interviewed. These household samples were selected from Census area data in all countries other than France (where telephone directories were used to select households) and the Netherlands (where postal registries were used to select households). Several WMH surveys (Belgium, Germany, Italy) used municipal resident registries to select respondents without listing households. The Japanese sample is the only totally un-clustered sample, with households randomly selected in each of the 11 metropolitan areas and one random respondent selected in each sample household. 16 of the 25 surveys are based on nationally representative household samples. d For the purposes of cross-national comparisons we limit the sample to those 18+. e The response rate is calculated as the ratio of the number of households in which an interview was completed to the number of households originally sampled, excluding from the denominator households known not to be eligible either because of being vacant at the time of initial contact or because the residents were unable to speak the designated languages of the survey. The weighted average response rate is 69.3%. f People's Republic of China g The newer Colombian survey in Medellin was classified as upper-middle income country (due to a change of classification by The World Bank) although the original survey Colombia was classified as a low-lower middle income country. For more information, please see footnote a.
Appendix
Appendix Table 2 . Age at selected percentiles on the standardized age of onset distributions of DSM-IV specific phobia with projected lifetime risk at age 75.
Country
Ages at selected percentiles the projected risk for these countries is at age 65 because the age range of these surveys is between 18-65. b the projected risk for this country is at age 64 because the age range of this survey is between 18-64.
